一种活体减弱的NS1缺陷疫苗候选人,用于原产于牛群的甲型 (H5N1) 流感类别2.3.4.4.b病毒
Ahmed Mostafa1,2, Chengjin Ye3, Ramya S Barre3
1Host-pathogen interactions (HPI) and Disease Intervention and Prevention (DIP) programs, Texas Biomedical Research Institute, San Antonio, TX, USA. aelsayed@txbiomed.org.
NPJ vaccines
|July 12, 2025
概括
一种新的H5N1流感疫苗候选者LPhTXdNS1显示出对公共健康的前景. 这种减弱的病毒是安全的,并在单剂量后有效地保护小鼠免受致命的H5N1禽流感挑战.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 公共卫生 公共卫生
背景情况:
- 禽流感病毒 (AIV) 构成重大公共卫生风险,因季节性疫苗有效性有限而加剧.
- 自2024年3月以来,美国家禽和牛中出现H5N1类第2.3.4.4b的出现引发了流行病的担忧.
研究的目的:
- 开发和评估一种安全且具有免疫性H5N1候选疫苗.
- 评估一种非结构蛋白1 (NS1) 缺乏突变型流感病毒对H5N1病毒的保护功效.
主要方法:
- 来自低致病性H5N1菌株的非结构蛋白1 (NS1) 缺乏突变 (LPhTXdNS1) 的发展.
- 在体外评估LPhTXdNS1衰减和复制效率.
- 在鼻内注射后,对小鼠模型 (C57BL/6J) 的安全性,免疫性和保护功效的评估.
主要成果:
- 在实验室中,LPhTXdNS1表现出衰减,复制减少,IFNβ促进体激活受损.
- 与对照组相比,LPhTXdNS1免疫的小鼠显示病毒复制和病原性显著减少.
- 单次鼻入剂量LPhTXdNS1给予了对致命的野生型H5N1病毒的强有力的保护.
结论:
- 缺少NS1的H5N1突变病毒 (LPhTXdNS1) 是一种安全且减弱的疫苗候选物.
- LPhTXdNS1有效诱导针对H5N1禽流感的保护性免疫反应.
- 这项研究强调了LPhTXdNS1作为减轻H5N1流行风险的战略的潜力.
相关概念视频
00:57Viral Recombination
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
01:27Influenza
Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...